The FDA on September 4, 2012 approved BOSULIF® (Bosutinib) for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior therapy. BOSULIF® tablets are a product of Pfizer, Inc.
Bottom Ad
Advertisement
Subscribe
